Biotech company Prometheus Biosciences has received $10 million from German company Dr. Falk Pharma after reaching a milestone under its collaboration agreement.
The funds were awarded after Prometheus developed and commercialized its second program, PR600, a precision antibody for the treatment of patients with inflammatory bowel disease.
The Dr. Falk Pharma partnership allowed Prometheus to "accelerate the PR600 program by sharing costs, resources and drug development know-how, which has resulted in the achievement of this important milestone within the first year of our collaboration," Prometheus President and CEO Mark McKenna,said in a June 21 news release.
Prometheus said it plans to file an investigational new drug application in the third quarter and explore PR600's use in indications beyond IBD.